Literature DB >> 23071279

CCR2(+)CCR5(+) T cells produce matrix metalloproteinase-9 and osteopontin in the pathogenesis of multiple sclerosis.

Wakiro Sato1, Atsuko Tomita, Daijyu Ichikawa, Youwei Lin, Hitaru Kishida, Sachiko Miyake, Masafumi Ogawa, Tomoko Okamoto, Miho Murata, Yoshiyuki Kuroiwa, Toshimasa Aranami, Takashi Yamamura.   

Abstract

Multiple sclerosis (MS) is a demyelinating disease of the CNS that is presumably mediated by CD4(+) autoimmune T cells. Although both Th1 and Th17 cells have the potential to cause inflammatory CNS pathology in rodents, the identity of pathogenic T cells remains unclear in human MS. Given that each Th cell subset preferentially expresses specific chemokine receptors, we were interested to know whether T cells defined by a particular chemokine receptor profile play an active role in the pathogenesis of MS. In this article, we report that CCR2(+)CCR5(+) T cells constitute a unique population selectively enriched in the cerebrospinal fluid of MS patients during relapse but not in patients with other neurologic diseases. After polyclonal stimulation, the CCR2(+)CCR5(+) T cells exhibited a distinct ability to produce matrix metalloproteinase-9 and osteopontin, which are involved in the CNS pathology of MS. Furthermore, after TCR stimulation, the CCR2(+)CCR5(+) T cells showed a higher invasive potential across an in vitro blood-brain barrier model compared with other T cells. Of note, the CCR2(+)CCR5(+) T cells from MS patients in relapse are reactive to myelin basic protein, as assessed by production of IFN-γ. We also demonstrated that the CCR6(-), but not the CCR6(+), population within CCR2(+)CCR5(+) T cells was highly enriched in the cerebrospinal fluid during MS relapse (p < 0.0005) and expressed higher levels of IFN-γ and matrix metalloproteinase-9. Taken together, we propose that autoimmune CCR2(+)CCR5(+)CCR6(-) Th1 cells play a crucial role in the pathogenesis of MS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23071279      PMCID: PMC3496198          DOI: 10.4049/jimmunol.1202026

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells.

Authors:  Eun Mi Hur; Sawsan Youssef; M Edward Haws; Susan Y Zhang; Raymond A Sobel; Lawrence Steinman
Journal:  Nat Immunol       Date:  2006-12-03       Impact factor: 25.606

2.  Metalloproteinases control brain inflammation induced by pertussis toxin in mice overexpressing the chemokine CCL2 in the central nervous system.

Authors:  Henrik Toft-Hansen; Richard Buist; Xue-Jun Sun; Angela Schellenberg; James Peeling; Trevor Owens
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

Review 3.  Multiple sclerosis: a complicated picture of autoimmunity.

Authors:  Henry F McFarland; Roland Martin
Journal:  Nat Immunol       Date:  2007-09       Impact factor: 25.606

4.  Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.

Authors:  Benjamin M Segal; Cris S Constantinescu; Aparna Raychaudhuri; Lilianne Kim; Rosanne Fidelus-Gort; Lloyd H Kasper
Journal:  Lancet Neurol       Date:  2008-09       Impact factor: 44.182

5.  Human T cells that are able to produce IL-17 express the chemokine receptor CCR6.

Authors:  Satya P Singh; Hongwei H Zhang; John F Foley; Michael N Hedrick; Joshua M Farber
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

Review 6.  Th17 Cells and autoimmune encephalomyelitis (EAE/MS).

Authors:  Toshimasa Aranami; Takashi Yamamura
Journal:  Allergol Int       Date:  2008-06       Impact factor: 5.836

Review 7.  A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis.

Authors:  Howard L Weiner
Journal:  J Neurol       Date:  2008-03       Impact factor: 4.849

Review 8.  Multiple sclerosis: an immune or neurodegenerative disorder?

Authors:  Bruce D Trapp; Klaus-Armin Nave
Journal:  Annu Rev Neurosci       Date:  2008       Impact factor: 12.449

9.  Cutting edge: Human Th17 cells are identified as bearing CCR2+CCR5- phenotype.

Authors:  Wakiro Sato; Toshimasa Aranami; Takashi Yamamura
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

10.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis.

Authors:  John S Tzartos; Manuel A Friese; Matthew J Craner; Jackie Palace; Jia Newcombe; Margaret M Esiri; Lars Fugger
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

View more
  22 in total

1.  MMP-9 deficiency shelters endothelial PECAM-1 expression and enhances regeneration of steatotic livers after ischemia and reperfusion injury.

Authors:  Hiroyuki Kato; Naohisa Kuriyama; Sergio Duarte; Pierre-Alain Clavien; Ronald W Busuttil; Ana J Coito
Journal:  J Hepatol       Date:  2014-01-08       Impact factor: 25.083

Review 2.  CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.

Authors:  Guillaume Martin-Blondel; David Brassat; Jan Bauer; Hans Lassmann; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

3.  Cytochrome P450 1B1 Contributes to the Development of Angiotensin II-Induced Aortic Aneurysm in Male Apoe(-/-) Mice.

Authors:  Shyamala Thirunavukkarasu; Nayaab S Khan; Chi Young Song; Hafiz U Ghafoor; David D Brand; Frank J Gonzalez; Kafait U Malik
Journal:  Am J Pathol       Date:  2016-06-11       Impact factor: 4.307

4.  Matrix Metalloproteinase 9 and Osteopontin Interact to Support Synaptogenesis in the Olfactory Bulb after Mild Traumatic Brain Injury.

Authors:  Melissa A Powell; Raiford T Black; Terry L Smith; Thomas M Reeves; Linda L Phillips
Journal:  J Neurotrauma       Date:  2019-01-10       Impact factor: 5.269

5.  Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets.

Authors:  Anne Monette; Antigoni Morou; Nadia A Al-Banna; Louise Rousseau; Jean-Baptiste Lattouf; Sara Rahmati; Tomas Tokar; Jean-Pierre Routy; Jean-François Cailhier; Daniel E Kaufmann; Igor Jurisica; Réjean Lapointe
Journal:  J Clin Invest       Date:  2019-03-26       Impact factor: 14.808

6.  Gatekeeper role of brain antigen-presenting CD11c+ cells in neuroinflammation.

Authors:  Magdalena Paterka; Volker Siffrin; Jan O Voss; Johannes Werr; Nicola Hoppmann; René Gollan; Patrick Belikan; Julia Bruttger; Jérôme Birkenstock; Steffen Jung; Enric Esplugues; Nir Yogev; Richard A Flavell; Tobias Bopp; Frauke Zipp
Journal:  EMBO J       Date:  2015-11-26       Impact factor: 11.598

7.  Evidence for a role for the adaptive immune response in human term parturition.

Authors:  Nardhy Gomez-Lopez; Rodrigo Vega-Sanchez; Marisol Castillo-Castrejon; Roberto Romero; Karen Cubeiro-Arreola; Felipe Vadillo-Ortega
Journal:  Am J Reprod Immunol       Date:  2013-01-24       Impact factor: 3.886

Review 8.  The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis.

Authors:  Abbas Mirshafiey; Babak Asghari; Ghasem Ghalamfarsa; Farhad Jadidi-Niaragh; Gholamreza Azizi
Journal:  Sultan Qaboos Univ Med J       Date:  2014-01-27

9.  Leukocyte Gene Expression and Plasma Concentration in Multiple Sclerosis: Alteration of Transforming Growth Factor-βs, Claudin-11, and Matrix Metalloproteinase-2.

Authors:  Gholamreza Hassanzadeh; Samaneh Hosseini Quchani; Mohammad Ali Sahraian; Farid Abolhassani; Mohammad Ali Sadighi Gilani; Masoomeh Dehghan Tarzjani; Fatemeh Atoof
Journal:  Cell Mol Neurobiol       Date:  2016-01-14       Impact factor: 5.046

10.  Biomarkers in Multiple Sclerosis: An Up-to-Date Overview.

Authors:  Serafeim Katsavos; Maria Anagnostouli
Journal:  Mult Scler Int       Date:  2013-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.